Click here to get full coverage on Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates  Yahoo Finance

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Market Outlook: Is IOVA a cyclical or defensive stock - Global Markets & Intraday High Probability Alerts - خودرو بانک

Market Outlook: Is IOVA a cyclical or defensive stock - Global Markets & Intraday High Probability Alerts  خودرو بانک

Market Outlook: Is IOVA a cyclical or defensive stock - Global Markets & Intraday High Probability Alerts - خودرو بانک

Click here to get full coverage on Why Iovance Biotherapeutics (IOVA) Is Up 8.2% After Health Canada Approves Amtagvi for Melanoma - simplywall.st

Why Iovance Biotherapeutics (IOVA) Is Up 8.2% After Health Canada Approves Amtagvi for Melanoma  simplywall.st

Why Iovance Biotherapeutics (IOVA) Is Up 8.2% After Health Canada Approves Amtagvi for Melanoma - simplywall.st

Click here to get full coverage on $IOVA stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

$IOVA stock is up 10% today. Here's what we see in our data.  Quiver Quantitative

$IOVA stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on IOVA Stock Drops 6% on $350M Common Stock Offering - Zacks Investment Research

IOVA Stock Drops 6% on $350M Common Stock Offering  Zacks Investment Research

IOVA Stock Drops 6% on $350M Common Stock Offering - Zacks Investment Research

Click here to get full coverage on If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today - The Motley Fool

If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today  The Motley Fool

If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today - The Motley Fool

Click here to get full coverage on Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million - Yahoo Finance

Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million  Yahoo Finance

Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million - Yahoo Finance

Click here to get full coverage on Tech Rally: Can IOVA benefit from deglobalization - July 2025 PostEarnings & High Conviction Buy Zone Alerts - خودرو بانک

Tech Rally: Can IOVA benefit from deglobalization - July 2025 PostEarnings & High Conviction Buy Zone Alerts  خودرو بانک

Tech Rally: Can IOVA benefit from deglobalization - July 2025 PostEarnings & High Conviction Buy Zone Alerts - خودرو بانک

Click here to get full coverage on New Analyst Forecast: $IOVA Given $20.0 Price Target - Quiver Quantitative

New Analyst Forecast: $IOVA Given $20.0 Price Target  Quiver Quantitative

New Analyst Forecast: $IOVA Given $20.0 Price Target - Quiver Quantitative

Click here to get full coverage on 1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street - The Motley Fool

1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street  The Motley Fool

1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street - The Motley Fool

Click here to get full coverage on IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - Yahoo Finance

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi  Yahoo Finance

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - Yahoo Finance

Click here to get full coverage on Iovance Biotherapeutics (IOVA) Raises US$350 Million in Equity Offering - Yahoo Finance

Iovance Biotherapeutics (IOVA) Raises US$350 Million in Equity Offering  Yahoo Finance

Iovance Biotherapeutics (IOVA) Raises US$350 Million in Equity Offering - Yahoo Finance

Click here to get full coverage on Resistance Check: Can IOVA grow without external funding - Portfolio Gains Summary & Free Real-Time Volume Trigger Notifications - خودرو بانک

Resistance Check: Can IOVA grow without external funding - Portfolio Gains Summary & Free Real-Time Volume Trigger Notifications  خودرو بانک

Resistance Check: Can IOVA grow without external funding - Portfolio Gains Summary & Free Real-Time Volume Trigger Notifications - خودرو بانک

Click here to get full coverage on $IOVA stock is down 3% today. Here's what we see in our data. - Quiver Quantitative

$IOVA stock is down 3% today. Here's what we see in our data.  Quiver Quantitative

$IOVA stock is down 3% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth - Yahoo Finance

Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth  Yahoo Finance

Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth - Yahoo Finance

Click here to get full coverage on H.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization News - Yahoo Finance

H.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization News  Yahoo Finance

H.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization News - Yahoo Finance

Click here to get full coverage on Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada - Yahoo Finance

Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada  Yahoo Finance

Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada - Yahoo Finance

Click here to get full coverage on Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance

Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges  Yahoo Finance

Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance

Click here to get full coverage on IOVA Stock Drops 6% on $350M Common Stock Offering - Nasdaq

IOVA Stock Drops 6% on $350M Common Stock Offering  Nasdaq

IOVA Stock Drops 6% on $350M Common Stock Offering - Nasdaq

Click here to get full coverage on Iovance: Thin Margins, Dilution Threat Keep Risk-Skewed (NASDAQ:IOVA) - Seeking Alpha

Iovance: Thin Margins, Dilution Threat Keep Risk-Skewed (NASDAQ:IOVA)  Seeking Alpha

Iovance: Thin Margins, Dilution Threat Keep Risk-Skewed (NASDAQ:IOVA) - Seeking Alpha

Click here to get full coverage on Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 (NASDAQ:IOVA) - Seeking Alpha

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 (NASDAQ:IOVA)  Seeking Alpha

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 (NASDAQ:IOVA) - Seeking Alpha

Click here to get full coverage on Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data - Yahoo Finance

Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data  Yahoo Finance

Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data - Yahoo Finance

Click here to get full coverage on Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Nasdaq

Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection  Nasdaq

Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Nasdaq

Click here to get full coverage on Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations  Yahoo Finance

Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

Click here to get full coverage on Iovance Biotherapeutics Soars as Health Canada Approves Amtagvi T Cell Therapy - StocksToTrade

Iovance Biotherapeutics Soars as Health Canada Approves Amtagvi T Cell Therapy  StocksToTrade

Iovance Biotherapeutics Soars as Health Canada Approves Amtagvi T Cell Therapy - StocksToTrade

Click here to get full coverage on Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug - RTTNews

Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug  RTTNews

Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug - RTTNews

Click here to get full coverage on Why Iovance Biotherapeutics Stock Got Mashed on Monday - The Motley Fool

Why Iovance Biotherapeutics Stock Got Mashed on Monday  The Motley Fool

Why Iovance Biotherapeutics Stock Got Mashed on Monday - The Motley Fool

Click here to get full coverage on Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm - PR Newswire

Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm  PR Newswire

Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm - PR Newswire

Click here to get full coverage on Iovance Biotherapeutics Secures Canadian Approval for Groundbreaking Therapy - StocksToTrade

Iovance Biotherapeutics Secures Canadian Approval for Groundbreaking Therapy  StocksToTrade

Iovance Biotherapeutics Secures Canadian Approval for Groundbreaking Therapy - StocksToTrade

Click here to get full coverage on $IOVA stock is up 3% today. Here's what we see in our data. - Quiver Quantitative

$IOVA stock is up 3% today. Here's what we see in our data.  Quiver Quantitative

$IOVA stock is up 3% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on New Analyst Forecast: $IOVA Given $25.0 Price Target - Quiver Quantitative

New Analyst Forecast: $IOVA Given $25.0 Price Target  Quiver Quantitative

New Analyst Forecast: $IOVA Given $25.0 Price Target - Quiver Quantitative

Click here to get full coverage on Cancer Cell Therapy Pioneer Iovance Biotherapeutics to Showcase Progress at Key September Conferences - Stock Titan

Cancer Cell Therapy Pioneer Iovance Biotherapeutics to Showcase Progress at Key September Conferences  Stock Titan

Cancer Cell Therapy Pioneer Iovance Biotherapeutics to Showcase Progress at Key September Conferences - Stock Titan

Click here to get full coverage on Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman - PR Newswire

Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman  PR Newswire

Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman - PR Newswire

Click here to get full coverage on Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA) - Seeking Alpha

Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA)  Seeking Alpha

Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA) - Seeking Alpha

Click here to get full coverage on Palo Alto Investors LP Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat

Palo Alto Investors LP Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA  MarketBeat

Palo Alto Investors LP Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat

Click here to get full coverage on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth  simplywall.st

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st

Click here to get full coverage on Iovance Biotherapeutics Grants Inducement Stock Options to New Employees - Quiver Quantitative

Iovance Biotherapeutics Grants Inducement Stock Options to New Employees  Quiver Quantitative

Iovance Biotherapeutics Grants Inducement Stock Options to New Employees - Quiver Quantitative

Click here to get full coverage on IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm  PR Newswire

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA - PR Newswire

Click here to get full coverage on 182,370 Stock Options at $2.54: Iovance Biotherapeutics Expands Team with 20 New Hires - Stock Titan

182,370 Stock Options at $2.54: Iovance Biotherapeutics Expands Team with 20 New Hires  Stock Titan

182,370 Stock Options at $2.54: Iovance Biotherapeutics Expands Team with 20 New Hires - Stock Titan

Click here to get full coverage on $IOVA stock is up 9% today. Here's what we see in our data. - Nasdaq

$IOVA stock is up 9% today. Here's what we see in our data.  Nasdaq

$IOVA stock is up 9% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Iovance Earnings: Revenue Soars 93% as Revolutionary Cancer Treatment Reaches Major Milestone - Stock Titan

Iovance Earnings: Revenue Soars 93% as Revolutionary Cancer Treatment Reaches Major Milestone  Stock Titan

Iovance Earnings: Revenue Soars 93% as Revolutionary Cancer Treatment Reaches Major Milestone - Stock Titan

Click here to get full coverage on IOVA 2-DAY DEADLINE ALERT: Iovance’s (IOVA) CFO Resigns - GlobeNewswire

IOVA 2-DAY DEADLINE ALERT: Iovance’s (IOVA) CFO Resigns  GlobeNewswire

IOVA 2-DAY DEADLINE ALERT: Iovance’s (IOVA) CFO Resigns - GlobeNewswire

Click here to get full coverage on Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha

Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience  Seeking Alpha

Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha

Click here to get full coverage on First-Ever T Cell Therapy for Solid Tumors: Iovance's Amtagvi Gets Historic Canada Approval - Stock Titan

First-Ever T Cell Therapy for Solid Tumors: Iovance's Amtagvi Gets Historic Canada Approval  Stock Titan

First-Ever T Cell Therapy for Solid Tumors: Iovance's Amtagvi Gets Historic Canada Approval - Stock Titan

Click here to get full coverage on Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025] - Trefis

Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025]  Trefis

Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025] - Trefis

Click here to get full coverage on Iovance Soars on Amtagvi Success: What’s Next? - StocksToTrade

Iovance Soars on Amtagvi Success: What’s Next?  StocksToTrade

Iovance Soars on Amtagvi Success: What’s Next? - StocksToTrade

Click here to get full coverage on Insider Purchase: Chief Commercial Officer of $IOVA Buys 30,000 Shares - Quiver Quantitative

Insider Purchase: Chief Commercial Officer of $IOVA Buys 30,000 Shares  Quiver Quantitative

Insider Purchase: Chief Commercial Officer of $IOVA Buys 30,000 Shares - Quiver Quantitative

Click here to get full coverage on IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire

IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit  GlobeNewswire

IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire

Click here to get full coverage on Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman - GlobeNewswire

Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman  GlobeNewswire

Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman - GlobeNewswire

Click here to get full coverage on Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit  PR Newswire

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Click here to get full coverage on DEADLINE ALERT for IOVA, DNUT, and MSTR: The Law Offices of - GlobeNewswire

DEADLINE ALERT for IOVA, DNUT, and MSTR: The Law Offices of  GlobeNewswire

DEADLINE ALERT for IOVA, DNUT, and MSTR: The Law Offices of - GlobeNewswire

Click here to get full coverage on Capital Fund Management S.A. Grows Stake in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat

Capital Fund Management S.A. Grows Stake in Iovance Biotherapeutics, Inc. $IOVA  MarketBeat

Capital Fund Management S.A. Grows Stake in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat

Click here to get full coverage on Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 - Yahoo Finance

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025  Yahoo Finance

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 - Yahoo Finance

Click here to get full coverage on Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 4.5% - Here's What Happened - MarketBeat

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 4.5% - Here's What Happened  MarketBeat

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 4.5% - Here's What Happened - MarketBeat

Click here to get full coverage on IOVA 8-DAY DEADLINE ALERT: Iovance’s (IOVA) Promising Cell - GlobeNewswire

IOVA 8-DAY DEADLINE ALERT: Iovance’s (IOVA) Promising Cell  GlobeNewswire

IOVA 8-DAY DEADLINE ALERT: Iovance’s (IOVA) Promising Cell - GlobeNewswire

Click here to get full coverage on Why Iovance Biotherapeutics Stock Is Under Pressure? - StocksToTrade

Why Iovance Biotherapeutics Stock Is Under Pressure?  StocksToTrade

Why Iovance Biotherapeutics Stock Is Under Pressure? - StocksToTrade

Click here to get full coverage on Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug  Seeking Alpha

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha

Click here to get full coverage on Iovance falls after missing Q2 expectation (IOVA:NASDAQ) - Seeking Alpha

Iovance falls after missing Q2 expectation (IOVA:NASDAQ)  Seeking Alpha

Iovance falls after missing Q2 expectation (IOVA:NASDAQ) - Seeking Alpha

Click here to get full coverage on Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman - GlobeNewswire

Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman  GlobeNewswire

Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman - GlobeNewswire

Click here to get full coverage on Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Second-Quarter Results - 富途牛牛

Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Second-Quarter Results  富途牛牛

Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Second-Quarter Results - 富途牛牛

Click here to get full coverage on IOVA CLASS ACTION: A Class Action was filed against Iovance - GlobeNewswire

IOVA CLASS ACTION: A Class Action was filed against Iovance  GlobeNewswire

IOVA CLASS ACTION: A Class Action was filed against Iovance - GlobeNewswire

Click here to get full coverage on Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman - PR Newswire

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman  PR Newswire

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman - PR Newswire

Click here to get full coverage on Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025] - Trefis

Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025]  Trefis

Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025] - Trefis

Click here to get full coverage on Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA - Nasdaq

Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA  Nasdaq

Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA - Nasdaq

Click here to get full coverage on Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)  GlobeNewswire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Click here to get full coverage on IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire

IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL,  GlobeNewswire

Iovance Biotherapeutics Inc (IOVA)

Price Chart

Key Statistics

Technicals

About IOVA

Latest News

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Market Outlook: Is IOVA a cyclical or defensive stock - Global Markets & Intraday High Probability Alerts - خودرو بانک

Why Iovance Biotherapeutics (IOVA) Is Up 8.2% After Health Canada Approves Amtagvi for Melanoma - simplywall.st

Advanced Charts

Top Gainers

Top Losers